Multi-omics approach reveals gene co-alterations and survival benefit in ovarian cancer patients under platinum-based adjuvant therapy

Multi-omics approach reveals gene co-alterations and survival benefit in ovarian cancer patients under platinum-based adjuvant therapy

Saved in:

Bibliographic Details
Main Authors:	Ning Ding, Jiahui Chen, Xiaotian Zhao, Minyi Zhu, Qiuxiang Ou, Jiaohui Pang, Luxi Ruan, Ying Zhang, Wei Sun, Xiaoxiang Chen
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2025-11-01
Series:	Genes and Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352304225001175
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
by: Amelia M. Jernigan, et al.
Published: (2013-01-01)

Exploring the efficacy and constraints of platinum nanoparticles as adjuvant therapy in silicosis management
by: Ge Ban, et al.
Published: (2025-12-01)

GPT2 mediates glutamine metabolism-driven metabolic alterations in platinum-resistant ovarian cancer cells
by: Adriana Ponton-Almodovar, et al.
Published: (2025-08-01)

Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
by: Wang Caixia, et al.
Published: (2025-01-01)

Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
by: Bhatt Aditi, et al.
Published: (2024-07-01)

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01)

Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope
by: Jan Brancewicz, et al.
Published: (2025-06-01)

Immunohistochemistry‐based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy
by: Csilla Olah, et al.
Published: (2025-01-01)

ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs
by: T. A. Bogush, et al.
Published: (2020-05-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
by: Qiran Wei, et al.
Published: (2024-11-01)

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
by: Yong Wu, et al.
Published: (2025-03-01)

Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma
by: Kenjiro Okada, et al.
Published: (2025-07-01)

Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer
by: Yoon Suk Lee, et al.
Published: (2025-01-01)

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
by: Michal M Hoppe, et al.
Published: (2021-03-01)

Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
by: Xin Cui, et al.
Published: (2024-10-01)

Overcoming PARP Inhibitor and Platinum Resistance with WEE1 Inhibitors in Ovarian Cancer
by: Ilaria Colombo
Published: (2021-10-01)

Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion
by: Jiong Ma, et al.
Published: (2024-12-01)

Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer
by: Jing Li, et al.
Published: (2024-12-01)

The gold complex auranofin sensitizes platinum resistant epithelial ovarian cancer cells to cisplatin
by: Farah H. Abdalbari, et al.
Published: (2025-06-01)

Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis
by: İrem Öner, et al.
Published: (2025-06-01)

Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer
by: Charlotte McRae, et al.
Published: (2025-06-01)

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
by: Afshin Dowlati, et al.
Published: (2025-03-01)

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
by: Maria Delgado-Ortet, et al.
Published: (2025-06-01)

Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
by: Luxitaa Goenka, et al.
Published: (2024-10-01)

The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer
by: Radu-Dumitru Dragomir, et al.
Published: (2025-03-01)

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer
by: TIAN Yanan, ZHENG Hui, YAN Tianqing, ZHANG Heng, LU Renquan, GUO Lin
Published: (2025-04-01)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
by: Young Shin Chung, et al.
Published: (2017-01-01)

Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
by: Li-Rong Yang, et al.
Published: (2024-11-01)

The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors
by: Baoyue Pan, et al.
Published: (2025-08-01)

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity
by: Rachel M. Hurley, et al.
Published: (2025-06-01)

Comparative Analysis between Two Anticancer Drugs: Platinum Complexes and Camptothecin in Ovarian Cancer Treatment
by: Zhou Yuhan
Published: (2025-01-01)

Deep learning based on ultrasound images to predict platinum resistance in patients with epithelial ovarian cancer
by: Chang Su, et al.
Published: (2025-05-01)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
by: Nicholas Cardillo, et al.
Published: (2022-10-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Incorporating genotype information in a precise prediction model for platinum sensitivity in epithelial ovarian cancer
by: Nai-Yi Du, et al.
Published: (2025-01-01)

Immunohistochemical parameters of serous ovarian carcinomas and possible mechanism of development of resistance to platinum-based drugs
by: G. V. Zhukova, et al.
Published: (2024-09-01)

Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
by: Tamaki Tanaka, et al.
Published: (2025-06-01)

Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies
by: Ece Esin, et al.
Published: (2019-12-01)